O60674 (JAK2_HUMAN) Homo sapiens (Human)
Tyrosine-protein kinase JAK2 UniProtKBInterProSTRINGInteractive Modelling
1132 aa; Sequence (Fasta)
Available Structures
162 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Structure of human JAK2 FERM/SH2 in complex with Erythropoietin Receptor |
Heteromer P19235; | 100.0 | ||||
| Structure of human JAK2 FERM/SH2 in complex with Leptin Receptor |
Heteromer P48357; | 100.0 | 1×SO4; | |||
| Crystal Structure of the E372K LNK SH2 Domain mutant in Complex with a JAK2 pY813 Phosphopeptide |
Heteromer O09039; | 100 | 1×CL; | |||
| Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with a JAK2 activation loop phospho… |
Heteromer P18031; | 100 | 1×TRS; 1×EDO; 3×CL; 2×NA; | |||
| Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with monophosphorylated JAK2 activa… |
Heteromer P18031; | 100 | 2×TRS; | |||
| Crystal structure of PTP1B D181A/Q262A phosphatase domain with JAK2 activation loop phosphopeptide |
Heteromer P18031; | 100 | 1×PO4; | |||
| Crystal structure of PTP1B D181A/Q262A/C215A phosphatase domain with JAK2 activation loop phosphope… |
Heteromer P18031; | 100 | 1×TRS; | |||
| X-ray co-crystal structure of compound 27 in with complex JAK2 | homo-2-mer | 99.28 | 2×YT8; | |||
| The crystal structure of JAK2 in complex with Compound 31 | homo-2-mer | 99.29 | 2×YT0; 1×DMS; 1×EDO; | |||
| JAK2 crystal structure in complex with Compound 13 | homo-2-mer | 98.93 | 2×YSI; 1×EDO; | |||
| Crystal structure of JAK2 JH2-K539L | homo-2-mer | 98.52 | 2×ATP; 2×MG; 1×GOL; | |||
| Crystal Structure of the FERM-SH2 Domains of Jak2 | monomer | 100.0 | ||||
| JAK2 kinase (JH1 domain) in complex with compound 9 | monomer | 100 | 1×1K3; 1×GOL; | |||
| JAK2 kinase (JH1 domain) in complex with 2,6-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL… | monomer | 100 | 1×0X5; | |||
| Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that… | monomer | 100.0 | 1×9ZS; | |||
| JAK2 kinase (JH1 domain) triple mutant in complex with compound 12 | monomer | 98.99 | 1×0NV; | |||
| JAK2 kinase (JH1 domain) in complex with compound 30 | monomer | 100 | 1×0NH; | |||
| High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-114. | monomer | 100 | 1×Y5D; | |||
| Crystal structure of JAK2 JH1 in complex with momelotinib | monomer | 100 | 1×C87; 1×MLI; | |||
| Crystal structure of JAK2 JH1 in complex with ilginatinib | monomer | 100 | 1×S59; 1×DMS; | |||
| Crystal structure of JAK2 JH1 in complex with cerdulatinib | monomer | 100 | 1×S5I; | |||
| Crystal structure of JAK2 JH1 in complex with gandotinib | monomer | 100 | 1×QQC; | |||
| High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to PN5-150. | monomer | 100.0 | 1×EDO; 1×Y5G; | |||
| Crystal structure of JAK2 JH1 in complex with pacritinib | monomer | 100 | 1×6T3; | |||
| Crystal structure of JAK2 JH1 in complex with lestaurtinib | monomer | 100 | 1×2V9; | |||
| Fragment based discovery of JAK-2 inhibitors | monomer | 100 | 1×5B3; | |||
| Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | monomer | 100 | 1×953; 1×GOL; | |||
| Crystal structure of JAK2 JH1 in complex with itacitinib | monomer | 100 | 1×S4R; | |||
| Fragment based discovery of JAK-2 inhibitors | monomer | 100 | 1×5B1; | |||
| JAK2 kinase (JH1 domain) triple mutant in complex with compound 7 | monomer | 98.96 | 1×0NU; | |||
| Structure of Janus kinase 2 with a pyrrolotriazine inhibitor | monomer | 100 | 1×J2I; | |||
| High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to YM2-059 | monomer | 100.0 | 1×4LY; | |||
| JAK2 kinase (JH1 domain) in complex with the inhibitor TRANS-4-[(8AS)-2-[(1R)-1-HYDROXYETHYL]IMIDAZ… | monomer | 100 | 1×1J5; | |||
| High-resolution crystal structure of human JAK2 kinase domain (JH1) bound to type-II inhibitor BBT5… | monomer | 100.0 | 1×046; 1×EDO; | |||
| JAK2 in complex with 4-(2-amino-8-methoxyquinazolin-6-yl)phenol | monomer | 99.31 | 1×9I5; | |||
| Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | monomer | 100.0 | 1×GOL; 1×VVQ; | |||
| JAK2 in complex with 4-{8-methoxy-2-[(1-methyl-1H-pyrazol-4-yl)amino]quinazolin-6-yl}phenol | monomer | 99.31 | 1×9I8; | |||
| Crystal Structure of JAK2 complexed with a potent quinoxaline ATP site inhibitor | monomer | 100 | 1×DQX; | |||
| JAK2 in complex with 4-(2-{[5-(dimethylamino)pentyl]amino}-8-{[(2S)-1-hydroxypropan-2-yl]amino}quin… | monomer | 99.31 | 1×9HR; | |||
| Fragment based discovery of JAK-2 inhibitors | monomer | 100 | 1×5B2; | |||
| Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders | monomer | 100.0 | 1×QUP; | |||
| Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In… | monomer | 98.92 | 1×7GT; | |||
| Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In… | monomer | 99.31 | 1×7GY; | |||
| JAK2 JH1 in complex with JNJ-7706621 (Crystal Form 2) | monomer | 100.0 | 1×SKE; | |||
| Crystals structure of Jak2 with a 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitor | monomer | 100.0 | 1×17P; | |||
| Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In… | monomer | 99.31 | 1×7GS; | |||
| CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)… | monomer | 100.0 | 1×50V; | |||
| Triazolopyridine-based Inhibitor of Janus Kinase 2 | monomer | 100 | 1×88A; 1×SO4; | |||
| JAK2 JH1 in complex with JNJ-7706621 | monomer | 100.0 | 1×SKE; 2×SO4; 2×GOL; | |||
| JAK2 JH1 in complex with MA9-086 | monomer | 100 | 1×R6S; | |||
| JAK2 kinase (JH1 domain) with 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE | monomer | 100 | 1×0X2; | |||
| Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In… | monomer | 99.31 | 1×7GX; | |||
| CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-7-[(DIMETHYL-1,3-THIAZOL-2-YL… | monomer | 100.0 | 1×50W; | |||
| JAK2 kinase (JH1 domain) mutant P1057A in complex with TG101209 | monomer | 99.65 | 1×CL; 1×ZN; 2×1M3; | |||
| Human JAK2 JH1 domain in complex with Baricitinib | monomer | 100.0 | 2×EDO; 1×3JW; | |||
| Human JAK2 JH1 domain in complex with Ruxolitinib | monomer | 100.0 | 3×EDO; 1×RXT; | |||
| JAK2 JH1 in complex with PN4-014 | monomer | 100 | 1×R5S; | |||
| Fragment-based discovery of 6-arylindazole JAK inhibitors | monomer | 99.31 | 1×6DP; | |||
| The structural basis of Janus Kinase 2 inhibition by a potent and specific pan-Janus kinase inhibit… | monomer | 99.65 | 1×IZA; | |||
| Crystal structure of Jak2 complexed with a potent 2,8-diaryl-quinoxaline inhibitor | monomer | 100.0 | 1×NVB; | |||
| Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for In… | monomer | 99.28 | 1×7GV; | |||
| JAK2 kinase (JH1 domain) in complex with compound 8 | monomer | 100.0 | 1×15V; | |||
| Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable… | monomer | 100 | 1×JAK; | |||
| Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634 | monomer | 99.65 | 1×2HB; | |||
| Crystal structures of JAK1 and JAK2 inhibitor complexes | monomer | 99.65 | 1×MI1; | |||
| Co-crystal structure of jak2 with thienopyridine 8 | monomer | 100.0 | 1×0TP; | |||
| JAK2 kinase (JH1 domain) in complex with TG101209 | monomer | 100.0 | 1×1M3; | |||
| CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-[(2S)-2,3-DIHYDROXYPROPYL]… | monomer | 100.0 | 1×50O; | |||
| Crystal structure of JAK2 kinase domain in complex with compound 30 | monomer | 100 | 1×OV0; | |||
| Structure determination of Aurora Kinase in complex with inhibitor | monomer | 99.65 | 1×L0I; | |||
| CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1-CARBOXAMIDE INHIBITOR | monomer | 100.0 | 1×4OK; | |||
| Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for th… | monomer | 98.94 | 1×7GZ; | |||
| Discovery and Optimization of C-2 Methyl Imidazo-pyrrolopyridines as Potent and Orally Bioavailable… | monomer | 100 | 1×1RS; | |||
| co-crystal structure of Jak2 with thienopyridine 19 | monomer | 100.0 | 1×6TP; | |||
| Crystal structure of JAK2 JH1 with type II inhibitor YLIU-04-105-1 | monomer | 100.0 | 1×I6C; 1×GOL; | |||
| Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors | monomer | 100.0 | 1×BJG; | |||
| Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T… | monomer | 100.0 | 1×4HZ; | |||
| Crystal Structure of JAK2 in complex with compound 25 | monomer | 99.31 | 1×D7D; | |||
| JAK2 JH1 in complex with baricitinib | monomer | 100 | 1×3JW; | |||
| JAK2 JH1 in complex with ruxolitinib | monomer | 100 | 1×RXT; | |||
| JAK2 in complex with 4-(2-amino-8-{[(2S)-1-hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluo… | monomer | 99.31 | 1×9I2; 1×GOL; | |||
| Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity | monomer | 98.62 | 1×QZ8; | |||
| JAK2 JH1 in complex with PN4-073 | monomer | 100 | 1×RXT; | |||
| JAK2 JH1 in complex with BL2-057 | monomer | 100 | 1×R6V; | |||
| Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T… | monomer | 100 | 1×467; | |||
| JAK2 JH1 in complex with PN3-115 | monomer | 100 | 1×R61; | |||
| Janus Kinase 2 Inhibitors | monomer | 100.0 | 1×JZH; 1×NA; | |||
| 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2 | monomer | 100.0 | 1×1P6; | |||
| Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T… | monomer | 100.0 | 1×4HW; | |||
| JAK2 JH1 in complex with BL2-084 | monomer | 100 | 1×R6P; | |||
| JAK2 JH1 in complex with SY5-103 | monomer | 100 | 1×R5Y; | |||
| A Novel Chemotype of Kinase Inhibitors | monomer | 100.0 | 1×3KC; | |||
| JAK2 JH1 in complex with BL2-096 | monomer | 100 | 1×R6V; | |||
| JAK2 JH1 in complex with Fedratinib | monomer | 100 | 1×2TA; | |||
| CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)… | monomer | 100.0 | 1×50Y; | |||
| JAK2 JH1 in complex with PN2-123 | monomer | 100 | 1×XZS; | |||
| JAK2 JH1 in complex with SG3-179 | monomer | 100 | 1×5W2; | |||
| JAK2 JH1 in complex with BL2-110 | monomer | 100 | 1×RG4; | |||
| JAK2 JH1 in complex with PN2-118 | monomer | 100 | 1×R6M; | |||
| Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 3 | monomer | 100.0 | 1×U8P; 1×GOL; | |||
| Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the T… | monomer | 100.0 | 1×VJK; | |||
| 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2 | monomer | 100.0 | 1×1P5; | |||
| Crystal structure of JAK2 with Compound 11 | monomer | 99.64 | 1×UWP; | |||
| Aminoalkylpyrimidine Inhibitor Complexes with JAK2 | monomer | 99.65 | 1×3O4; | |||
| Aminoalkylpyrimidine Inhibitor Complexes with JAK2 | monomer | 99.65 | 1×O19; | |||
| Inhibitors of Jak2 Kinase domain | monomer | 99.28 | 1×AZ5; | |||
| Crystal structure of JAK2 in complex with peficitinib | monomer | 99.29 | 1×9T6; | |||
| Structural basis of Jak2 inhibition by the type II inhibtor NVP-BBT594 | monomer | 100.0 | 1×046; 1×MLI; | |||
| Inhibitors of Jak2 Kinase domain | monomer | 98.91 | 1×LMM; 2×ACT; | |||
| Inhibitors of Jak2 Kinase domain | monomer | 98.91 | 1×F9J; 2×ACE; | |||
| Inhibitors of Jak2 Kinase domain | monomer | 98.91 | 1×XWW; 2×ACT; | |||
| Human JAK2 JH1 domain in complex with PROTAC-intermediate linker handle 4 | monomer | 100.0 | 1×U8J; 1×TRS; 1×EDO; | |||
| Crystal structure of JAK2 JH2 in complex with Bemcentinib | monomer | 98.92 | 1×Q8U; 5×GOL; | |||
| Crystal Structure of the E596A V617F Mutant JAK2 Pseudokinase Domain Bound to Mg-ATP | monomer | 98.17 | 1×ATP; 1×MG; 1×GOL; | |||
| Crystal structure of JAK2 JH2-V617F in complex with Z902-A1 | monomer | 98.55 | 5×GOL; 2×ACT; 1×Q9X; | |||
| JAK2-JH2 | monomer | 98.91 | 1×36H; | |||
| Crystal structure of JAK2 JH2-V617F in complex with Z902-A3 | monomer | 98.91 | 2×GOL; 1×Q7F; | |||
| Crystal structure of JAK2 JH2-V617F in complex with HTS-A3 | monomer | 98.54 | 2×GOL; 1×T7I; | |||
| Crystal structure of JAK2 JH2 in complex with Z902-A3 | monomer | 98.91 | 1×Q7F; 4×GOL; | |||
| Crystal structure of JAK2 JH2-V617F in complex with CB76 | monomer | 98.91 | 7×GOL; 1×Q8N; | |||
| Crystal structure of JAK2 JH2-V617F in complex with JNJ-7706621 | monomer | 98.91 | 2×GOL; 1×SKE; | |||
| Crystal structure of JAK2 JH2-V617F in complex with Reversine | monomer | 98.91 | 5×GOL; 1×AD5; | |||
| Crystal structure of JAK2 JH2-R683S | monomer | 98.54 | 1×GOL; 1×T7I; | |||
| Crystal structure of the Jak2 pseudokinase domain (Mg-ATP-bound form) | monomer | 98.91 | 1×ATP; 1×MG; 2×ACT; | |||
| Crystal structure of the Jak2 pseudokinase domain mutant V617F (Mg-ATP-bound form) | monomer | 98.91 | 1×ATP; 1×MG; | |||
| Crystal structure of JAK2 JH2-V617F in complex with Cdk2 inhibitor IV | monomer | 98.54 | 3×GOL; 1×AQG; | |||
| Crystal structure of the Jak2 pseudokinase domain (apo form) | monomer | 98.91 | 2×GOL; | |||
| JAK2 Pseudokinase in complex with NU6140 | monomer | 98.91 | 1×AQG; | |||
| JAK2 JH2 IN COMPLEX WITH JAK292 | monomer | 98.91 | 1×E8I; 1×GOL; | |||
| Crystal structure of JAK2 JH2-V617F in complex with Bemcentinib | monomer | 98.54 | 1×Q8U; | |||
| JAK2 Pseudokinase in complex with AZD7762 | monomer | 98.91 | 1×YDJ; | |||
| JAK2 Pseudokinase in complex with JNJ7706621 | monomer | 98.91 | 1×SKE; | |||
| JAK2 Pseudokinase in complex with AT9283 | monomer | 98.91 | 1×35R; | |||
| JAK2 Pseudokinase in complex with BI-D1870 | monomer | 98.91 | 1×584; | |||
| JAK2 JH2 in complex with PRT062607 | monomer | 98.9 | 2×GOL; 1×3YT; 1×ACT; | |||
| JAK2 JH2 in complex with diaminopyrimidine JAK040 | monomer | 98.9 | 1×J9D; 1×GOL; 1×DMS; | |||
| Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with CDK2-IV | monomer | 98.9 | 1×AQG; | |||
| Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with HTSA3 | monomer | 98.53 | 1×Q2Q; 3×GOL; | |||
| JAK2 JH2 in complex with NVP-BSK805 | monomer | 98.9 | 1×DQX; 2×GOL; 1×DMS; | |||
| JAK2 JH2 IN COMPLEX WITH JAK315 | monomer | 98.9 | 1×E3W; 1×GOL; | |||
| JAK2 Pseudokinase V617F in complex with AT9283 | monomer | 98.53 | 1×35R; | |||
| Crystal structure of JAK2 JH2 (pseudokinase domain) in complex with Reversine | monomer | 98.9 | 1×AD5; 1×GOL; | |||
| JAK2 JH2 in complex with IKK-2 Inhibitor VI | monomer | 98.9 | 1×IK1; 3×GOL; 1×ACT; | |||
| JAK2 JH2 in complex with 63552444 | monomer | 98.9 | 1×E4V; 3×GOL; | |||
| Crystal Structure of JAK2-V617F pseudokinase domain in complex with Compound 2 | monomer | 98.53 | 1×EKT; 8×EDO; | |||
| JAK2 JH2 in complex with a diaminopyrimidine | monomer | 98.9 | 1×8MY; 5×GOL; 1×DMS; 1×ACT; | |||
| JAK2 JH2 in complex with JAK179 | monomer | 98.9 | 1×GOL; 1×M4G; | |||
| JAK2 JH2 in complex with JAK020 | monomer | 98.9 | 1×GOL; 1×VPJ; | |||
| Crystal structure of JAK2 JH2-I559F | monomer | 98.53 | ||||
| JAK2 JH2 in complex with GLPG0634 | monomer | 98.9 | 4×GOL; 1×2HB; 1×ACT; 1×DMS; | |||
| JAK2 JH2 in complex with JAK170 | monomer | 98.9 | 1×M3Y; | |||
| JAK2 JH2 in complex with JAK249 | monomer | 98.9 | 1×DVY; | |||
| JAK2 JH2 in complex with JAK146 | monomer | 98.9 | 1×M3A; | |||
| JAK2 JH2 in complex with BI-D1870 | monomer | 98.9 | 4×GOL; 1×7DZ; | |||
| JAK2 JH2 in complex with JAK190 | monomer | 98.88 | 1×GOL; 1×M57; | |||
| JAK2 JH2 in complex with XMU-MP-1 | monomer | 98.9 | 1×5BS; 1×GOL; 1×ACT; | |||
| JAK2 JH2 in complex with JAK168 | monomer | 98.9 | 1×M4P; | |||
| JAK2 JH2 in complex with NU6102 | monomer | 98.89 | 1×GOL; 1×4SP; | |||
| JAK2 JH2 in complex with AT9283 | monomer | 98.9 | 2×GOL; 1×35R; 1×ACT; 1×DMS; | |||
| JAK2 JH2 in complex with JNJ-7706621 | monomer | 98.9 | 1×SKE; 2×GOL; 1×DMS; | |||
| JAK2 JH2 in complex with JAK064 | monomer | 98.89 | 1×VPS; 1×GOL; | |||
| JAK2 JH2 in complex with JAK067 | monomer | 98.87 | 1×V4D; | |||
9 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6e2p.1.A | monomer | 0.81 | 100.00 | |||
| 4oli.1.A | monomer | 0.71 | 46.90 | |||
| 4fl3.1.A | monomer | 0.59 | 1×MG; | 24.81 | ||
| 1fmk.1.A | monomer | 0.58 | 26.09 | |||
| 1y57.1.A | monomer | 0.58 | 26.09 | |||
| 1opl.2.A | monomer | 0.56 | 25.07 | |||
| 4xi2.1.A | monomer | 0.55 | 24.86 | |||
| 2j0j.1.A | monomer | 0.50 | 23.00 | |||
| 2j0k.1.A | monomer | 0.50 | 21.96 | |||